Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Analysis of Placental Cell Free DNA and RNA Predicts Gestational Complications

By LabMedica International staff writers
Posted on 20 Oct 2020
A recent paper revealed that circulating cell-free nucleic acids (DNA and RNA) shed from the placenta into the mother's blood during the first trimester of pregnancy could be used to predict potentially serious complications such as ischemic placental disease and gestational diabetes. More...


Although analysis of maternal plasma cell-free content has been employed for screening of genetic abnormalities within a pregnancy, limited attention has been paid to its use for the detection of adverse pregnancy outcomes based on placental function.

In this light, investigators at the University of California, Los Angeles (USA) analyzed the cell-free DNA and RNA content of 102 maternal and 25 cord plasma samples obtained from a group of pregnant women between February 2017 and January 2019. A total of 160 of the participants gave birth by the end of the study.

Results revealed that during the first trimester, placenta-specific DNA increased prior to the subsequent development of gestational diabetes with no change in patients with pre-eclampsia while decreasing with maternal obesity. Moreover, using cell-free RNA sequencing, adverse pregnancy outcomes revealed 71 differentially expressed genes early in pregnancy. In particular, the investigators noted upregulation of the S100A8, MS4A3, and MMP8 genes that had been already associated with adverse pregnancy outcomes but also the upregulation of BCL2L15 and the downregulation of ALPL that had never been associated with adverse pregnancy outcomes.

These results enabled the investigators to construct a classifier with a positive predictive ability of 0.91 for adverse pregnancy outcomes, 0.86 for pre-eclampsia alone, and 0.64 for gestational diabetes.

"Our research points to a promising approach that could improve outcomes for mothers and their babies using existing technologies," said senior author Dr. Sherin Devaskar, professor of pediatrics at the University of California, Los Angeles. "If confirmed in larger studies, cell-free DNA blood tests may help identify issues in the placenta as an indicator of a healthy mother and fetus. The novelty of this research is being able to break down a mother's DNA and be able to hone in on the health of the placenta - something that researchers have never been able to do before. This research warrants application of automated methodologies in multi-center trials to improve future testing and screening for all women."

The study was published in the October 13, 2020, online edition of the journal Epigenetics.

Related Links:
University of California, Los Angeles


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.